Tagged with Policy

USA With the passage of the US Inflation Reduction Act (IRA) that will begin to take effect this year, the biopharma industry continues to grapple with the implications of the new law while deciding how to move forward in response to it. At the recent BIO CEO and Investor Conference, stakeholders…

Germany In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the country’s health insurance system by distributing the financial burden amongst all healthcare stakeholders, yet biopharma companies stand to be hit…

USA David H. Crean, Managing Partner for Cardiff Advisory, discusses the economic impact of the signing and implementation of the Inflation Reduction Act (IRA) on the biopharmaceutical industry and innovation.   America’s biopharmaceutical research companies are researching and developing new medicines to meet unmet needs and continuing research and development even…

France An early bronchiolitis outbreak has put French paediatric hospital services under pressure and forced the government to react with the provision of EUR 150 million in emergency funds, but this crisis is by no means the first for French healthcare. France’s healthcare system, based on a statutory health insurance (SHI)…

Brazil Although Brazil is one of the world’s top pharma markets, with the highest market value in Latin America, and has made major strides towards universal healthcare, the country continues to recover from its worst recession ever and the fallout from its disastrous COVID-19 response. Brazilian voters are preparing for a…

United Kingdom After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack of consistency and coordination as well as cases of discrimination within the system. As a result of the report, the…

Europe Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) shares her views on the pharma industry’s response to COVID-19 and Europe’s preparedness for future health crises. She also discusses the reach and ambition of the Pharma Strategy and addresses the issues around equitable access.   …

Japan The latest healthcare and pharma news from Japan, including Shionogi’s COVID-19 pill, the Japanese parliament’s green light for emergency approvals of drugs and vaccines and Hitachi’s partnership with Invivoscribe.   Shionogi’s COVID-19 pill  (Reuters) The future of Shionogi & Co Ltd’s experimental treatment, S-217622, is still uncertain. The company recently…

Australia Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the first national election since the start of the COVID-19 pandemic, and it resulted in an historic change of government. The…

Australia Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped by community and stakeholder feedback.   Australia’s National Medicines Policy (NMP), gazetted in 2000, is being revised and the draft policy was…

USA A roundup of the latest news from US life sciences and healthcare, including sweeping healthcare reform in the state of California; how revolutionary billionaire Mark Cuban’s newly launched affordable online pharmacy Cost Plus Drug Co. can be; DHL’s USD 400 million expansion of its pharmaceutical and medical device supply chain…

USA The latest from US health care policy, including the Senate budget deal funding for a range of major health care priorities; Biden’s proposed Advanced Research Projects Agency that would reshape the government’s medical research efforts; the Senate Finance Chair’s proposal to lower prescription drug prices; the FDA’s internal investigation into…